Hematology
<乌鸦传媒 class="page-description">More in Hematology
News, features, and commentary about cancer-related issues
Experts at ASH debate quadruplet therapy, dexamethasone modulation, and novel approaches
Response rate of 70% at day 28 with remestemcel-L
Phase III trial sparks discussion on defining and managing high-risk smoldering myeloma
News, features, and commentary about cancer-related issues
DREAMM-7 findings help pave the way for Blenrep's return
Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity
But no overall survival benefit seen in confirmatory trial
SAHARA rounds out this year's notable trials on blood transfusions in critically ill patients
Better disease outcomes, measures of cognition, and quality-of-life vs standard care, study finds
New standard of care for patients in first remission?
Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more
Treatment tied to fewer vaso-occlusive pain events, hospitalizations versus placebo
AMPLIFY trial paves the way for FDA approval of acalabrutinib plus venetoclax
